35 C
Vientiane
Monday, May 5, 2025
spot_img
Home Blog Page 2176

Meta Health Appoints Dr Bernard Ng as Chairman of the Board and Group CEO

Executive Director of 5Digital Pte Ltd, Dr Bernard Ng, takes over as Chairman of the Board (“Chairman”) and Group CEO as current Chairman and CEO, Mr Chua Kheng Choon, assumes the role of SVP of Engineering, with effect from 7 June 2022
The management reshuffle comes at a pivotal stage of transformation as the Group endeavors to look beyond metal manufacturing and explore opportunities in the digital healthcare sector and to drive next phase of growth

SINGAPORE Media OutReach6 June 2022 – Meta Health Limited (“META” or the “Company”, and together with its subsidiaries, the “Group”) is pleased to announce a strategic restructuring of its management team as it endeavors to diversify and expand into the digital healthcare industry. Executive Director of 5Digital Pte Ltd (a wholly-owned subsidiary of the Company) (“5Digital”), Dr Bernard Ng, will be re-designated to the role of Chairman and Group CEO, where he will oversee the Group’s pivot to the digital healthcare space. This new appointment will allow the current Chairman and CEO, Mr Chua Kheng Choon, to transition into the role of SVP of Engineering, where he will continue to head the operations for the metal engineering business of the Group. Both Dr Ng and Mr Chua will assume their new roles with effect from 7 June 2022.

Dr Ng brings over 20 years of professional experience in the pharmaceutical and consumer health industries to his appointment as Chairman and Group CEO. He obtained his medical degree from the National University of Malaysia in 1999 and his MBA from the University of Melbourne in 2011. Prior to joining the Group, Dr Ng served as Chief Medical Officer, Head of Global Medical and Clinical Affairs at Bayer Consumer Healthcare.

He is a strong believer of digital transformation and spends his time plugged into start-ups that are pioneering technology with the potential to create significant value for medical professionals and their patients. As Group CEO, he will leverage his expertise of medicine and digital transformation to lead META’s pivot into the consumer health industry.

As one of the founders of META, Mr Chua has accumulated over 35 years of experience in the precision metal stamping industry. Under his leadership, the Company has grown steadily from its inception as a stamping contractor to its position as a one-stop provider for mechanical manufacturing products and services. Thanks to Mr Chua’s on-going efforts and guidance, revenue from the metal stamping business rebounded strongly in FY2021, growing 29% y-o-y to S$41.7m and returning to profitability last year. As Mr Chua moves into his new role, he will continue to focus on delivering quality engineering solutions and growing the customer base of the Group’s metal engineering business.

META has deepened its presence in the digital health enabled services in the last year. The anchor investment started with acquisition of an 85.07% stake in Gainhealth Pte Ltd.(“Gainhealth”), bringing primary care and central pharmacy services together with both online and offline sales channels. META also announced a conditional sale and purchase agreement with PT Gaido Digital Medika (“PT GDM”) and a share subscription agreement to take up to 10% stake in MedTel Healthcare Private Limited (“MedTel”). These strategic investments complement the Group’s vision of becoming a leading healthcare services company in Southeast Asia, providing personalized healthcare within a hand-picked ecosystem of online and offline care providers and e-pharmacies, while leveraging on the most up-to-date insights from research and data. The launch of “Digital Hospital” in Indonesia, a trademarked product by PT GDM, has gained significant traction. In an announcement by the G20 business council, Digital Hospital has been identified as a partner of the Indonesian Tourism Medical Association in early March 2022[1].

The new personnel changes will enable the Group to advance its strategic focus on digital healthcare and become the sector’s preferred solutions provider. Dr Ng will work alongside industry veteran and Chief Medical Officer of 5Digital, Dr Vas Metupalle, a healthcare entrepreneur with 17 years of experience under his belt. Having previously founded companies in the Teleradiology (Clarity) and Telemedicine (MyDoc) space, Dr Metupalle has vast regional experience in implementing diagnostic and outpatient healthcare services for corporate health and insurance industry partners. Together, Dr Ng and Dr Metupalle make up a strong team of medical experts who will lay the foundation of META’s further exploration efforts in the field.

Dr Bernard Ng said: “It is a great privilege for me to lead META and I would like to thank the Board of Directors for their trust. I look forward to working alongside the management team to explore new streams of business development opportunities and conducting a strategic review of existing businesses, and the implementation thereof, with a view to create value for shareholders. The Group will also look into accelerating our revenue and profit growth targets through strategic acquisitions and scaling of our current activities.

About Meta Health Limited

Meta Health Limited (META), formerly known as Metal Component Engineering Limited, was founded in 1987 in Singapore. With consistent focus on quality and engineering innovation, META has expanded its customer base by serving MNC (Multi-National-Corporation), EMS (Electronic Manufacturing Services), and SME (Small-Medium-Enterprise) globally. META has recently diversified into healthcare technology and services with investment into Gainhealth Pte. Ltd., a direct-to-consumer and high-growth omnichannel health and wellness platform. META is vertically integrated with licensed clinics with pharmacy, online self-branded ecommerce portals, and product placements on regional e-commerce portals.

For more information, visit , and

#MetaHealth

Disclaimer
This press release has been prepared by Meta Health Limited (“Company”) and its contents have been reviewed by the Company’s sponsor, ZICO Capital Pte. Ltd. (“Sponsor”), in accordance with Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited (“SGX-ST”) Listing Manual Section B: Rules of Catalist.

This press release has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr Alex Tan, Chief Executive Officer, ZICO Capital Pte. Ltd. at 77 Robinson Road, #06-03 Robinson 77, Singapore 068896, telephone (65) 6636 4201.

Drunk Robots Finds New Partners and Increases the Prize Pool in $METAL

LONDON, UK Media OutReach – 6 June 2022 – The epic and cool NFT game Drunk Robots has been fueled by the success of IDO and continues to find new friends in the crypto industry. The project team is working on improving the gameplay, expanding the community and significant and attractive changes in the economy of the p2e game.

The project community has exceeded 120 thousand active users, which is a huge success. All these players are immersed in the atmosphere of incredible adventures, mysterious opponents, heaps of booze, battles and valuable prizes.

More than 10k unique robots have many unique components and tools to make the player the best in the whole city of fallen machines. Players can upgrade 10 main stats, including weapons, hats, clothes, and other important components of winning and earning tokens.

In April, the project team went even further and announced four new collaborations. This time, the “robots” have partnered with well-known crypto projects that have thousands of fans: Avocado DAO, Skill Guilds, Infinity Force and Yield Guild Games SEA. Thanks to these announcements, the project has every chance to significantly expand the audience due to the growing involvement of the public and the interest of the audience from Southeast Asia.

Changes in tournament prizes for the best fighters of the city of fallen machines

The team also made significant changes to the economy. Now the pool of tokens that players could count on has been increased to 5 million for every three months. Players now need to be extra proficient in beating the crap out of their opponents, climbing to the very top of the table and earning a whopping 4,000 $METAL tokens on just one robot per month. It seems that many players will make this game their main source of income. And also from the second half of the new season, players need to crush the jaws of their opponents at least five times a 24 to get maximum profit.

About Drunk Robots

– blew up the P2E and NFT space and became the most rock and roll and stylish project of the year. Become an iron brutal warrior and conquer the city of fallen machines for fun and lots of booze at .

#DrunkRobots

SUNeVision Welcomes the Court of Appeal’s Ruling on Potential Breaches of Lease Conditions of Data Centers in HKSTP Industrial Estates

HONG KONG SAR – Media OutReach – 6 June 2022 – On 31 May 2022, the Court of Appeal allowed the appeal against the first instance judgement lodged by SUNeVision in a judicial review application, quashing the decision of the Hong Kong Science and Technology Parks Corporation (HKSTP) not to take immediate steps to rectify its failure or refusal to take reasonable steps to enforce restrictions in its leases against the operators of the data centers in the industrial estates it manages to sublet the leased premises or to allow third parties to occupy the leased premises. The Court of Appeal held that HKSTP has misconstrued the Occupation Restriction under its own Lease Restriction Policy and that it has also breached its duty of making reasonable inquiry when handling the complaints from SUNeVision. The Court of Appeal also directs HKSTP to reconsider SUNeVision’s complaints in accordance with the meaning of the Occupation Restriction in the Lease Restriction Policy as found by the Court.

1. SUNeVision welcomes the recent ruling of the Court of Appeal, which is positive for the long-term development of Hong Kong’s innovation and technology (I&T) sector. SUNeVision has been a strong supporter of Hong Kong’s vision to become an international I&T hub. The recent judgement of the Court of Appeal will help to create a healthy environment for the I&T industry in Hong Kong, in line with the National 14th Five-Year Plan.

2. Land resources in Hong Kong are scarce and precious. The government has allocated more than 200 hectares of land to HKSTP to operate three industrial estates in Tseung Kwan O, Yuen Long and Tai Po. HKSTP should properly and effectively utilize the land resources to support the I&T sector. As paragraph 11 of the judgement mentions, “the rationale behind the Lease Restriction Policy is that land in the industrial estates, granted at a preferential rate for the purpose of fostering the lessees’ development of industries or businesses which the Corporation has seen fit to promote, should be dedicated to such purposes and not used for rental gain”.

3. Some data center operators in Tseung Kwan O Industrial Estate have been operating in a way that involves subletting or permitting third parties to occupy the leased premises. Paragraph 104 of the judgement points out that “the Possession Restriction and the Occupation Restriction should be construed in such a way as to prohibit a grantee from running or operating a business in the Corporation’s property that amounts to in substance subleasing or subletting and a business that would not foster and facilitate the growth of local technology through intensive research and development activities”.

4. HKSTP must take all reasonable measures to enforce the lease conditions and prohibit operators from subletting the premises or allowing third parties to occupy the leased premises. In reality, the breaches of lease conditions by the lessees did not just happen recently, nor have the breaches been confined to data center operators. The breaches have taken place over a long period of time, as recent cases and prosecutions have shown. HKSTP should immediately rectify the problems to ensure tenants strictly comply with the lease conditions, otherwise the tenants must return their sites to the HKSTP or the government for proper use.

5. HKSTP is a statutory authority with substantial public land resources at its disposal. It is a critical organization tasked with fostering the development of Hong Kong’s innovation and technology. Hence, the HKSTP Board and management should undertake a thorough review to ensure all of its land is put to proper use for innovation. This is not just about ensuring that there are no breaches of the lease restrictions. It is also about utilizing the land more effectively. It is a fact that a significant number of sites in the industrial estates is lying idle or under-utilized. It is also a fact that some sites in the industrial estates are occupied by tenants that no longer serve any purpose in fostering innovation in Hong Kong. HKSTP must reallocate such sites to serve Hong Kong’s latest needs in research and innovation, and help nurture young and promising new companies. If there is excess land that HKSTP cannot properly utilize, it should be returned to the government for other important uses, such as public housing.

6. The National 14th Five-Year Plan clearly states its support for Hong Kong to develop into an international I&T hub. We sincerely hope HKSTP will work together with the industry to strengthen the city’s I&T sector.

About SUNeVision

SUNeVision (SEHK: 1686), the technology arm of Sun Hung Kai Properties (SEHK: 0016), is the largest data center provider in Hong Kong. We provide industry-leading carrier and cloud-neutral data center services with Asia’s number one connectivity. We connect providers of telecommunications, cloud, ISP, CDN, OTT from local, mainland China and global with enterprises of different businesses on our Asia leading data center ecosystem.

SUNeVision forms MEGA Campus by extending the connectivity edge from highly connected MEGA-i to other high-tier data centers, including MEGA Gateway, MEGA IDC, MEGA Plus and MEGA Two. Facilities on MEGA Campus are interconnected through a dedicated dark fibre network and around 15,000 cross-connects. Together with City PoPs of major submarine cables in our facilities, we enable our customers for direct connections to multi-cloud platforms and multi-cloud exchanges with the best connectivity in town. We are committed to supporting Hong Kong as a regional information hub and a strategic gateway to mainland China.

For more information, please visit SUNeVision’s , or .

#SUNeVision

UNFPA and The Lao Red Cross Partner to Strengthen Capacity on Blood management and services, Health Promotion and Disaster Preparedness

The United Nations Population Fund (UNFPA) and the Lao Red Cross (LRC) will collaborate for capacity Strengthening Programme on Blood Service and Management, Health Promotion and Disaster Preparedness, with a focus on Meung District, Bokeo Province.

AWS and HKSTP Announce Strategic Collaboration to Accelerate Innovation and Technology Development in Hong Kong

HONG KONG SAR – Media OutReach – 6 June 2022 – Amazon Web Services (AWS) and Hong Kong Science and Technology Parks Corporation (HKSTP) announced a strategic collaboration today, aiming to foster a robust Innovation and Technology (I&T) ecosystem in Hong Kong. With this collaboration, AWS and HKSTP will launch a series of programs under four key pillars to drive innovation of IT companies, startups, and researchers throughout their entire growth cycle – Research & Development, Technology Simulation, Co-incubation, and Talent and Culture Cultivation.

AWS and HKSTP announced a strategic collaboration today to accelerate Innovation and Technology development in Hong Kong. Present at the press conference were (from left to right) Michael Au, Assistant Director, Partnerships, HKSTP; Dr. Crystal Fok, Head of STP Platform, HKSTP; Chris So, Head of Business and Partner, Hong Kong, AWS; Perkins Ho, Senior Business Development Manager, Strategic Programs, Hong Kong & Taiwan, AWS

AWS and HKSTP announced a strategic collaboration today to accelerate Innovation and Technology development in Hong Kong. Present at the press conference were (from left to right) Michael Au, Assistant Director, Partnerships, HKSTP; Dr. Crystal Fok, Head of STP Platform, HKSTP; Chris So, Head of Business and Partner, Hong Kong, AWS; Perkins Ho, Senior Business Development Manager, Strategic Programs, Hong Kong & Taiwan, AWS

“HKSTP and AWS have been working closely for years in supporting high potential tech ventures to innovate, succeed and grow faster. We have witnessed the surging demand from businesses on cloud computing knowledge and innovation technologies. This partnership combines the scale and technology expertise of AWS, the undisputed cloud innovation leader, as well as HKSTP’s R&D, incubation and commercialization capabilities accumulated over the past 20 years, to accelerate the development of Hong Kong’s I&T ecosystem while firmly establishing the city’s status as a global innovation hub.” said Albert Wong, Chief Executive Officer, HKSTP.

“AWS is always committed to support the digital transformation of enterprises of all scales in Hong Kong,” said Robert Wang, Managing Director, Hong Kong & Taiwan, AWS. “Since 2014, AWS and HKSTP have been working together on a number of cloud programs and trainings. We are pleased to deepen our relationship with HKSTP and jointly address the various challenges the city faces in terms of talent, innovation, and technology commercialization.”

  • Research and Development: HKSTP is joining the AWS Open Data Sponsorship Program which extends Open Data access through STP Platform, to support local research teams, including those from universities and research laboratories. Utilizing AWS cloud services, AWS Open Data Sponsorship Program allows researchers worldwide to share and analyze datasets derived from latest studies on global pandemics, cancer, and more. The collaboration will allow researchers at HKSTP partner companies to improve efficiency, while saving costs and time needed for research and data processing.
  • Technology Simulation: It is often difficult to predict the success and optimal route for commercialization of new technologies in sectors such as Artificial Intelligence and Robotics. AWS will support STP Platform to visualize outcomes through Technology Simulation, allowing developers to conduct tests and simulations at lower costs. AWS and HKSTP will also form a ‘train-the-trainer’ program using AWS RoboMaker, allowing developers to effortlessly simulate applications under virtual 3D environments and test robotics solutions built with different coding languages, all with reduced costs and higher efficiency. Programs to support simulation of other emerging technologies will follow.
  • Co-incubation: AWS and HKSTP will continue to nurture startups and support their business growth. Targeting Software-as-a-Service (SaaS) startups, the first six-month acceleration program will provide training, technical and business consultation to help them unlock the potential of SaaS business model, enhance their SaaS products, and ultimately drive business growth and success.
  • Talent and Culture Cultivation: To nurture homegrown IT talents, AWS will utilize its global training and education resources to equip students and practitioners together with HKSTP. In the first phrase, AWS and HKSTP will provide technical training in biotechnology and AI for InnoHK clusters, enterprises, and startups. Based on the needs of the participating organization, AWS will also provide tailor-made capacity-building packages including talent training and Amazon innovation culture workshops.

AWS will hold its annual AWS Summit Hong Kong online on June 7 where professionals in the industry will gather and share insights into the latest cloud trends and industry best practices. HKSTP will set up a virtual booth at the Summit to share more information about their latest collaboration with AWS. Visit https://go.aws/3Ntu3w1 to register for AWS Summit.

About Hong Kong Science and Technology Parks Corporation

Hong Kong Science and Technology Parks Corporation (HKSTP) has for 20 continuous years committed to building up Hong Kong as an international innovation and technology hub to propel success for local and global pioneers today and tomorrow. HKSTP has established a thriving I&T ecosystem that is home to three unicorns and Hong Kong’s leading R&D hub with over 11,000 research professionals and over 1,000 technology companies focused on healthtech, AI and robotics, fintech and smart city technologies.

Established in 2001, we attract and nurture talent, accelerate and commercialise innovation and technology for entrepreneurs on their journey of growth in Hong Kong, to the Greater Bay Area, Asia and beyond. Our growing innovation ecosystem is built around our key locations of the Hong Kong Science Park in Shatin, InnoCentre in Kowloon Tong and three modern INNOPARKs in Tai Po, Tseung Kwan O and Yuen Long. The three INNOPARKs are realizing a vision of re-industrialisation for Hong Kong. The goal is sectors like advanced manufacturing, electronics and biotechnology are being reimagined for a new generation of industry.

Through our infrastructure, services, expertise and network of partnerships, HKSTP will help establish innovation and technology as a pillar of growth for Hong Kong, while reinforcing Hong Kong’s international I&T hub status as a launchpad for global growth at the heart of the GBA innovation powerhouse.

More information about HKSTP is available at .

About Amazon Web Services
For over 15 years, Amazon Web Services has been the world’s most comprehensive and broadly adopted cloud offering. AWS has been continually expanding its services to support virtually any cloud workload, and it now has more than 200 fully featured services for compute, storage, databases, networking, analytics, machine learning and artificial intelligence (AI), Internet of Things (IoT), mobile, security, hybrid, virtual and augmented reality (VR and AR), media, and application development, deployment, and management from 84 Availability Zones within 26 geographic regions, with announced plans for 24 more Availability Zones and eight more AWS Regions in Australia, Canada India, Israel, New Zealand, Spain, Switzerland, and the United Arab Emirates. Millions of customers—including the fastest-growing startups, largest enterprises, and leading government agencies—trust AWS to power their infrastructure, become more agile, and lower costs. To learn more about AWS, visit .

#AWS #AmazonWebServices

Comba Telecom Releases 4G/5G (8TR) Green Integrated Base Station Antenna

Support Operators Achieve Carbon Neutrality Targets

HONG KONG SAR – Media OutReach – 6 June 2022 – Comba Telecom Systems Holdings Limited (“Comba Telecom” or “the Group”, SEHK stock code: 2342), a global leading wireless solutions provider, today announced the release of 4G/5G (8TR) Green Integrated Base Station Antenna, which expands its tower top portfolio to support operators achieve carbon neutrality targets.

In the face of increasingly severe global climate change, green growth and carbon emissions reduction have become a global consensus. As carbon emissions and socio-economic development are interrelated, countries worldwide prioritize achieving the carbon neutrality targets, requiring the energy consumption restructuring of different industries. 5G-enabled technologies and connectivity, which empower the major verticals to digitalize and transform the way they operate, play an important role in combating climate change. With the mission to support net-zero goals, Comba Telecom, as a leading provider of wireless and communications systems, explores and innovates new architectures, solutions, and technologies of mobile antenna systems, and provides a series of forward-thinking solutions for operators to build green, low-carbon, intelligent and highly efficient 5G networks.

To support the low-carbon deployment of 5G networks, Comba Telecom has launched a high-end 4G/5G (8TR) integrated Base Station Antenna (BSA), which meets the capacity and coverage requirements, and has become the mainstream tower-top antenna solution for global 5G network construction.

For low-carbon network operation, Comba Telecom has released a low-loss and high-efficiency green antenna. With the adoption of Pin to Pin low-insertion-loss modular integration solution, low-insertion-loss phase shifters and feeder network integration is achieved, minimizing the antenna internal loss, and improving the antenna gains and efficiency. As a result, it will improve the base station’s coverage under the same input power, which is conducive to reducing the density of the base station. While within the same coverage area, the input power of the base station is lower, and its energy consumption is minimized.

Striving to build a green industry supply chain, reduce the carbon footprint in the manufacturing process and realize sustainability throughout the life cycle of the antenna, Comba Telecom introduced a new environmentally friendly coating process, using the ion beam coating to replace the traditional electroplating process which consumes high energy and causes environmental pollution. Also, Comba Telecom innovated and developed a lightweight, environmentally-friendly radome with low-dielectric constant through the application of foam-solid combination, modified thermoplastic material, and composite extrusion foaming processes. The whole process of manufacturing is pollution-free, and the product can be easily recycled and reused. In addition, the low dielectric constant, low loss, and low-density features help to reduce the weight of the antenna and improve its efficiency.

Comba Telecom will continue to accelerate 5G network evolution and technological advancement, enabling operators to build high-quality, high-efficient, green, and low-carbon new network infrastructure through technology and product innovation.

About Comba Telecom Systems Holdings Limited

Comba Telecom is a global leading wireless solutions provider with its own R&D facilities, manufacturing base and sales and service teams. The Group offers a comprehensive suite of products and services including base station antennas and subsystems, network products, services, and wireless transmission to its global customers. Headquartered in Hong Kong, with manufacturing bases and R&D centers in China, Comba Telecom provides wireless communication solutions and information application services to customers in more than 100 countries and regions around the world. Comba Telecom was included in the MSCI Hong Kong Small Cap Index in November 2019. Furthermore, the Group was included as a constituent stock of Hang Seng Composite SmallCap Index, Hang Seng Internet & Information Technology Index and other Hang Seng Family of Indexes, and the China-Hong Kong Stock Connect under the Shenzhen-Hong Kong Stock Connect in September 2020. For further information, please visit: www.comba-telecom.com

#CombaTelecom

Sunlight REIT secures an additional HK$800 million Sustainability-linked Loan from BOCHK

HONG KONG SAR – Media OutReach – 6 June 2022 – Henderson Sunlight Asset Management Limited (the “Manager“) and Bank of China (Hong Kong) (“BOCHK“) jointly announce that Sunlight Real Estate Investment Trust (“Sunlight REIT“) has secured its second tranche of HK$800 million sustainability-linked loan (“SLL“). Together with the first tranche of HK$500 million, this HK$1.3 billion SLL commitment represents a significant sustainable finance collaboration between Sunlight REIT and BOCHK, increasing the proportion of SLLs of Sunlight REIT to over 60% of total borrowings.

Mr. Keith Wu, Chief Executive Officer of the Manager (second from left), Ms. Vivian Yip, General Manager – Investment and Investor Relations of the Manager (left), Ms. Kennis Chong, Deputy General Manager, Global Corporate Banking Department of BOCHK (second from right) and Mr. Calvin Woo, Assistant General Manager, Global Corporate Banking Department of BOCHK (right) announce that Sunlight REIT has secured its second tranche of SLL from BOCHK.
Mr. Keith Wu, Chief Executive Officer of the Manager (second from left), Ms. Vivian Yip, General Manager – Investment and Investor Relations of the Manager (left), Ms. Kennis Chong, Deputy General Manager, Global Corporate Banking Department of BOCHK (second from right) and Mr. Calvin Woo, Assistant General Manager, Global Corporate Banking Department of BOCHK (right) announce that Sunlight REIT has secured its second tranche of SLL from BOCHK.

This SLL, which is an unsecured loan facility and has a tenure of four years, shall allow Sunlight REIT to enjoy interest margin privileges based on the achievement of predetermined environmental related sustainability performance targets, comprising reduction in energy consumption and indoor air quality certifications. The proceeds of this loan will be used for refinancing and general working capital.

Mr. Wu Shiu Kee, Keith, Chief Executive Officer of the Manager, said, “We are grateful for the unwavering support from BOCHK, which enables Sunlight REIT to achieve an important milestone in its sustainability journey. Reflecting the Manager’s firm commitment to linking business success with environmental solutions, the unsecured nature of this loan further strengthens the debt profile of Sunlight REIT. Looking ahead, we shall endeavour to continuously reinforce our sustainability platform, while striving to bring our long-standing partnership with BOCHK to the next level.”

Ms. Lu Ying, General Manager of Global Corporate Banking Department of BOCHK, said, “This SLL underscores Sunlight REIT’s commitment to put sustainability finance at the forefront of its priorities. BOCHK is delighted to continue to offer the SLL to Sunlight REIT. The loan supports Sunlight REIT to achieve its long-term sustainability goals while also enabling it to grow its business in a more sustainable way. BOCHK has been taking active steps to promote green finance. With its tailored green finance solutions, the Bank endeavours to work together with its customers to push forward the development of a green and low-carbon economy. ”

Disclaimer: The information contained in this press release does not constitute an offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for units in Sunlight REIT in Hong Kong or any other jurisdiction.

About Sunlight REIT

Listed on The Stock Exchange of Hong Kong Limited since 21 December 2006, Sunlight REIT (stock code: 435) is a real estate investment trust authorized by the Securities and Futures Commission and constituted by the amended and restated trust deed dated 10 May 2021 (the “Trust Deed“). It offers investors the opportunity to invest in a diversified portfolio of 11 office and five retail properties in Hong Kong with a total gross rentable area of over 1.2 million sq. ft.. The office properties are located in both core and decentralized business areas, while the retail properties are situated in regional transportation hubs, new towns and urban areas with high population density.

About the Manager
The Manager of Sunlight REIT is an indirect wholly-owned subsidiary of Henderson Land Development Company Limited. Its main responsibility is to manage Sunlight REIT and all of its assets in accordance with the Trust Deed in the sole interest of its unitholders.

About Bank of China (Hong Kong) Limited
Bank of China (Hong Kong) Limited (“BOCHK“) is committed to pursuing its strategic goal to “Build a First-class Regional Banking Group” and promoting sustainable and high-quality development. Capitalising on its advantages as a major commercial banking group in Hong Kong, BOCHK continues to increase local market penetration, captures business opportunities in the Greater Bay Area and actively expands its business development in Southeast Asia. We strive to provide customers with comprehensive, professional and high-quality services. Entering a new era of smart banking, we endeavour to become a customer-centric digital bank by enhancing customer experience with innovative technology and offering intelligent products and services.

As one of the three note-issuing banks and the sole clearing bank for Renminbi (“RMB“) business in Hong Kong, BOCHK has strong market positions in all major businesses. Our strong RMB franchise has made us the first choice for customers in RMB business. We have the most extensive branch network and diverse service platforms in Hong Kong, as well as efficient e-channels such as Internet and Mobile Banking services. We offer a comprehensive range of financial, investment and wealth management services to personal, corporate and institutional customers.

We are actively pushing forward our regional development and expanding our business in the Southeast Asian region. With our branches and subsidiaries in Thailand, Malaysia, Vietnam, the Philippines, Indonesia, Cambodia, Laos, Brunei and Myanmar, we support customers in the region with professional and high-quality financial services. Through close cooperation with our parent bank – Bank of China, we provide a full range of high-quality cross-border services to multinationals, crossborder customers, mainland enterprises going global, central banks and super-sovereign organisations.

As a leading commercial and internationalised regional bank with deep roots in Hong Kong for over 100 years, BOCHK upholds its mission of “Bridge China and the World for the Common Good”. We are committed to undertaking our corporate social responsibilities, promoting long-term and balanced sustainable development, and delivering greater value for our stakeholders and the community. BOC Hong Kong (Holdings) Limited is one of the largest listed companies on the Main Board of the Stock Exchange of Hong Kong, with stock code “2388” and ADR OTC Symbol “BHKLY”.

#SunlightREIT

The issuer is solely responsible for the content of this announcement.

PADCEV™ (enfortumab vedotin) treatment for Locally Advanced or Metastatic Urothelial Cancer receives market authorisation in Singapore

Enfortumab vedotin is the first antibody drug conjugate approved in Singapore for la/mUC patients who received a prior platinum-containing chemotherapy and a PD-1/L1 inhibitor.

SINGAPORE – Media OutReach – 6 June 2022 Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that PADCEV (enfortumab vedotin) has been approved by the Health Sciences Authority of Singapore as monotherapy for the treatment of adult patients with locally advanced (LA) or metastatic urothelial cancer (mUC) who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.

The Singapore approval follows the earlier European Commission (EC) approval of PADCEV on 13 April 2022. Singapore is among the first two countries in Asia Pacific (alongside Japan) to receive market authorisation. The EC approval is supported by data from the global phase 3 EV-301 trial that demonstrated an overall survival (OS) benefit compared with chemotherapy.

“This is a significant milestone for Singapore. The approval of enfortumab vedotin provides new treatment options for patients living with advanced urothelial cancer and have had limited treatment options and low survival rates. We look forward to working with other health authorities across the region to ensure more patients living with advanced urothelial cancer can access this new treatment option as soon as possible,” said Verma, Vivek, Head of Medical Affairs International Markets & Greater China, Astellas.

The EV-301 trial[1] compared enfortumab vedotin to chemotherapy in adult patients (n=608) with locally advanced or metastatic urothelial cancer who were previously treated with platinum-based chemotherapy and a PD-1/L1 inhibitor. At the time of the pre-specified interim analysis, patients who received enfortumab vedotin (n=301) in the trial lived a median of 3.9 months longer than those who received chemotherapy (n=307). Median OS was 12.9 vs. 9 months, respectively [Hazard Ratio=0.70 (95% Confidence Interval [CI]: 0.56, 0.89), p=0.001]. Across clinical trials, the most common adverse reactions with enfortumab vedotin were alopecia, fatigue, decreased appetite, peripheral sensory neuropathy, diarrhea, nausea, pruritus, dysgeusia, anemia, weight decreased, rash maculo-papular, dry skin, vomiting, aspartate aminotransferase increased, hyperglycemia, dry eye, alanine aminotransferase increased and rash.

Urothelial cancer is the most common type of bladder cancer, accounting for 90 per cent of all bladder cancer cases[2]. In the Asia Pacific region, an estimated 130,000 people were diagnosed with urothelial cancer in 2021, and more than 65,000 have died as a result of the disease[3]. Urothelial cancer is also found in the renal pelvis (where urine collects inside the kidney), ureter (tube that connects the kidneys to the bladder) and urethra[4].

PADCEV has received marketing authorization in the United States, Japan, Canada, the European Union (EU), Israel, The United Kingdom, Switzerland, Brazil and Singapore.


[1] Results from the EV-301 trial are intended to support global registrations for enfortumab vedotin.

[2] American Society of Clinical Oncology. Bladder cancer: introduction (9-20). https://www.cancer.net/cancer-types/bladder-cancer/introduction. Accessed March 16, 2022.

[3] Cancer Today. Bladder Cancer Factsheet 2020. https://gco.iarc.fr/today/data/factsheets/cancers/30-Bladder-fact-sheet.pdf. Accessed March 16, 2022.

[4] American Society of Clinical Oncology. Bladder cancer: introduction (9-20). https://www.cancer.net/cancer-types/bladder-cancer/introduction. Accessed March 16, 2022.

About PADCEV™ (enfortumab vedotin)

PADCEV is a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer[5]. Nonclinical data suggest the anticancer activity of PADCEV is due to its binding to Nectin-4 expressing cells followed by the internalization and release of the anti-tumor agent monomethyl auristatin E (MMAE) into the cell, which result in the cell not reproducing (cell cycle arrest) and in programmed cell death (apoptosis) [5] PADCEV is co-developed by Astellas and Seagen.

About the EV-301 Trial
The EV-301 trial () was a global, multicenter, open-label, randomized phase 3 trial designed to evaluate enfortumab vedotin versus physician’s choice of chemotherapy (docetaxel, paclitaxel or vinflunine) in 608 patients with locally advanced or metastatic urothelial ca Singapore Health Sciences Authority ncer who were previously treated with a PD-1/L1 inhibitor and platinum-based therapies[6]. The primary endpoint was overall survival and secondary endpoints included progression-free survival, overall response rate, duration of response and disease control rate, as well as assessment of safety/tolerability and quality-of-life parameters. Results were published in the

About Astellas
Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at .

About Seagen
Seagen Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on our marketed products and robust pipeline, visit and follow @SeagenGlobal on Twitter.

Important Safety Information
The Singapore approved package insert can be accessed at the Singapore Health Sciences Authority . Report any adverse events to Astellas Pharma Singapore Pte. Ltd. at pv@sg.astellas.com. Alternatively, adverse events may be reported to the Health Sciences Authority at Tel: 6866 1111, Fax: 6478 9069 or online at .

About the Astellas and Seagen Collaboration
Astellas and Seagen are co-developing enfortumab vedotin under a 50:50 worldwide development and commercialization collaboration. In the United States, Astellas and Seagen co-promote enfortumab vedotin. In the Americas outside the US, Seagen holds responsibility for commercialization activities and regulatory filings. Outside of the Americas, Astellas holds responsibility for commercialization activities and regulatory filings.

Astellas Cautionary Notes
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development), which is included in this press release is not intended to constitute an advertisement or medical advice.

Seagen Forward-Looking Statements
Certain statements made in this press release are forward-looking, such as those, among others, relating to the therapeutic potential of PADCEV, including its efficacy, safety and therapeutic uses, and the potential to make PADCEV available to patients in Europe. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, the possibilities that we may experience delays or setbacks in seeking pricing and reimbursement approvals or otherwise in commercializing PADCEV in Europe; that adverse events or safety signals may occur; and that adverse regulatory actions may occur. More information about the risks and uncertainties faced by Seagen is contained under the caption “Risk Factors” included in the company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.


[5] Challita-Eid P, Satpayev D, Yang P, et al. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Res 2016;76(10):3003-13. / PADCEV [package insert]. Northbrook, Ill.: Astellas Pharma US, Inc.

[6] Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med. 2021; 10.1056/NEJMoa2035807.